Amgen | AMGN - Sales Revenues

Stock Price
344.71
Daily Change
2.83 0.83%
Monthly
7.48%
Yearly
19.33%
Q1 Forecast
331.35

Amgen reported $9.56B in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
AbbVie USD 15.78B 360M Sep/2025
Agios Pharmaceuticals USD 12.9M 450K Sep/2025
ALKERMES USD 394.2M 3.5M Sep/2025
Amgen USD 9.56B 380M Sep/2025
Biogen USD 2.53B 70M Sep/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Bristol-Myers Squibb USD 12.2B 70M Sep/2025
Eli Lilly USD 17.6B 2.04B Sep/2025
Exelixis USD 597.8M 29.5M Sep/2025
Genmab DKK 5.86B 580M Jun/2025
Gilead Sciences USD 7.8B 700M Sep/2025
GlaxoSmithKline GBP 8.55B 557M Sep/2025
Glaxosmithkline GBP 11.52B 3.54B Sep/2025
Incyte USD 1.37B 310M Sep/2025
Ionis Pharmaceuticals USD 157M 295M Sep/2025
J&J USD 24.6B 610M Dec/2025
Merck USD 17.28B 1.47B Sep/2025
Moderna USD 1.02B 878M Sep/2025
Neurocrine Biosciences USD 794.9M 107.4M Sep/2025
Novartis USD 13.91B 144M Sep/2025
Novartis USD 14.36B 478M Sep/2025
Pfizer USD 16.7B 2B Sep/2025
PTC Therapeutics USD 211M 32.1M Sep/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
Takeda JPY 1.19T 80B Dec/2025
Teva Pharmaceutical Industries USD 14.63B 10M Dec/2025
Ultragenyx Pharmaceutical USD 160M 6.5M Sep/2025
Vertex Pharmaceuticals USD 3.08B 120M Sep/2025